| 摘要 |
The invention relates to the use of antagonists of a protease- activated receptor, PAR3, for the treatment of asthma. The presence of pro- inflammatory cytokines, such as TNF- alpha or ILl-beta, thrombin interacts with PAR3 resulting in the induction of GM-CSF to a level that is found in asthma. |
